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Abstract 
Background: Tamoxifen is used in endocrine treatment of breast cancer to inhibit estrogen signaling. A set of strati‑
fied ER‑positive and ER‑negative tumor sections was subjected to manual deposition of tamoxifen solution in order to 
investigate its spatial distribution upon exposure to interaction within thin tissue sections.
Methods: The localization of tamoxifen in tumor sections was assessed by matrix assisted laser deposition/ioniza‑
tion mass spectrometry imaging. The images of extracted ion maps were analyzed for comparison of signal intensity 
distributions.
Results: The precursor ion of tamoxifen (m/z 372.233) displayed heterogeneous signal intensity distributions in his‑
tological compartments of tumor tissue sections. The levels of tamoxifen in tumor cells compared with stroma were 
higher in ER‑positive tissues, whereas ER‑negative tissue sections showed lower signal intensities in tumor cells.
Conclusions: The experimental model was successfully applied on frozen tumor samples allowing for differentiation 
between ER groups based on distribution of tamoxifen.
Keywords: Human breast cancer, Tamoxifen treatment, MALDI‑mass spectrometry imaging, Estrogen receptor 
stratification, Drug localization, Drug quantification
© 2016 Végvári et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Breast cancer is the most common malignancy among 
women in the Western world, affecting approximately 
every tenth woman. In the past decades, there has been 
considerable improvement in the prognosis, which 
enhanced survival, although still 1500 women die each 
year from the disease in Sweden only. Breast cancer is 
treated locally with surgery and radiotherapy while sys-
temic treatment includes chemotherapy, endocrine ther-
apy and targeted drugs. The endocrine treatment involves 
blocking the estrogen receptor (ER) pathway and is a tar-
geted treatment inhibiting the binding of estrogen to the 
ER (using tamoxifen) or by removing the ligand estrogen 
(using aromatase inhibitors or oophorectomy). Despite 
new promising drugs, patients are still recurring due to 
a failure to respond to treatment. Drug resistance is one 
possible cause to therapy failure, however, the mecha-
nisms behind drug resistance are not fully understood. 
Additionally, with the exception for ER and HER2 status, 
there are no predictive factors used in the clinical routine 
for guidance in treatment sensitivity.
The proteins involved in drug uptake in breast cancer 
tissue have shown to play an active role in drug resistance 
[1], and we have in a previous study discovered glycopro-
teins involved in response to tamoxifen, distinguishing 
recurring from non-recurring breast cancer patients [2]. 
Altered expression profiles of target proteins have been 
studied using radioligand binding to characterize recep-
tor distribution and functional state [3]. Treatment fail-
ure may be explained by different patterns of drug uptake 
distribution. Localization of administered drugs is mostly 
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studied in animal models, which may provide limited 
insights to their molecular mechanism in humans. With 
the currently available biobanking samples we applied a 
recently developed methodology to investigate whether 
ER stratified human tumors can be distinguished upon 
exposure to tamoxifen in solution.
Matrix-assisted laser desorption/ionization-mass spec-
trometry imaging (MALDI-MSI) is an established tech-
nology used to localize molecules of various nature in 
tissue sections in order to investigate their spatial and 
temporal distributions in organs or whole body [4–7]. 
The technology of MALDI-MSI was introduced in 1994 
[8] and localizations of protein in brain sections was 
demonstrated soon after [9]. Since then MALDI-MSI has 
been applied to lateral and temporal localization of other 
molecules, including lipids [10], and drug compounds 
[11]. Due to the broad availability of MALDI mass spec-
trometers and the relatively simple sample preparation 
required, the methodology has been intensively devel-
oped in drug distribution analyses [11]. The detection of 
an orally administered drug compound directly in mouse 
tumor tissue surface using MALDI-MS was demonstrated 
by acquiring data in an array of positions [12]. Quantita-
tive analyses of drug molecules using MSI technology was 
investigated and compared with standard LC–MS/MS 
methods [13–17]. MALDI-MSI has been typically applied 
for drug imaging of low-molecular-weight compounds 
administered to experimental animals, utilizing the 
exceptional advantage that no chemical derivatization is 
required [18]. High resolution MSI significantly improved 
the localization of drug metabolites [19–22]. The 
approach allows simultaneous detection of pharmaco-
logically active compounds and their metabolites [4, 19], 
supporting pharmacokinetic (PK) and pharmacodynamic 
(PD) developments in the pharmaceutical industry, e.g., 
contributing to PK screening [23, 24]. Recently, we have 
introduced a novel methodology based on experimen-
tal models, when tissue sections from untreated animals 
were deposited with or submerged in drug solutions prior 
to MALDI-MS imaging analysis [25, 26]. This method has 
revealed specific localizations of compounds in heteroge-
neous tumor sections.
In this study, we investigated the localization of tamox-
ifen in five ER-positive and five ER-negative breast tumor 
sections using an experimental model by MALDI-MSI. 
In this model, tamoxifen was manually overlaid and incu-
bated on the tissue surface, after which the localization 
and quantification of its precursor ion was determined.
Methods
Patients
Frozen human breast cancer tissue was provided by the 
South Swedish Breast Cancer Tumor Bank. Ten samples 
with freshly frozen tumor tissues (ca. 5  ×  5  ×  5  mm 
each) from breast cancer patients were selected and ER 
was evaluated using immunohistochemistry (IHC) by a 
pathologist at the Department of Oncology and Pathol-
ogy in Lund. The definition of ER-positive is >10 % posi-
tive cells and negative is ≤10 % positive cells. We chose 
to include ER-positive tumors with  >75  % positive cells 
and ER-negative with 0  %. Five of the tumors were ER-
positive and five were negative. One ER-positive and 
one ER-negative tumor were excluded due to poor tis-
sue quality with few cancer cells. The ethical permission 
for this study was approved by the Ethical Committee of 
Lund (LU-240-01).
Sample preparation
Tamoxifen (CAS 10540-29-1; Mw  =  371.515  g/mol; 
IUPAC name: (Z)-2-[4-(1,2-diphenylbut-1-enyl)
phenoxy]-N,N-dimethylethanamine) was obtained in 
form of pills (Zitazonium™), each containing 10  mg 
active compound among Mg-stearate, A type carboxy-
methyl-Na starch, povidone K25, microcrystalline cellu-
lose, potato starch and lactose-monohydrate (108.2 mg). 
One pill was crushed and 1  mL DMSO was added in 
order to dissolve the powder. The suspension was then 
further diluted with distilled water in several steps until 
obtaining a clear solution at 0.1 mg/mL.
To characterize ionization properties, a dilution series 
of tamoxifen (0.001–10 µg/mL) was applied on a MALDI 
target plate and dried droplet sample spots were prepared 
by adding 1 µL of 3.5 mg/mL α-cyano-4-hydroxycinnamic 
acid (CHCA, from Sigma-Aldrich, St. Louis MO) matrix 
solution in 50 % acetonitrile (AcN)/0.1 % trifluoroacetic 
acid (TFA) to 1 µL tamoxifen solution.
Human breast tumor samples were cut at 15  µm 
thickness at −20  °C using a cryostat (Leica CM1950, 
Leica Biosystems, Nussloch, Germany) after transfer-
ring them from −80  °C and collected on glass slides 
(25 × 75 × 1 mm Superfrost Ultra Plus, Thermo Scien-
tific). For MALDI-MS imaging analysis each collected 
tissue section was treated with 100 % methanol (MeOH) 
for 5  min and covered with 500  µL of 2  µg/mL tamox-
ifen solution (aq.) followed by incubation in a humidity 
chamber for 1 h at room temperature. After removal of 
the excess solution, the sections were extensively washed 
with distilled water and then dried in air. The CHCA 
matrix solution at 7.5  mg/mL concentration (in 50  % 
AcN/0.1 % TFA) was then sprayed stepwise onto the tis-
sue surface using an airbrush (Aztek A470, Testor Corp., 
Rockford IL).
MALDI mass spectrometry imaging analysis
The MALDI-MS imaging acquisition was performed 
using a MALDI LTQ Orbitrap XL mass spectrometer 
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(Thermo Fisher Scientific, Bremen, Germany) with a 
method that employed 10 laser shots at 10 µJ. Automatic 
gain control was switched off. The tissue surface was 
sampled in meandering mode at 40, 50 or 80-µm raster 
step size. Full scans in profile mode were generated in a 
mass range from m/z 150 to 500 in the Orbitrap at reso-
lution of 60,000 (at m/z 400) in positive polarity.
Following data acquisition, the raw files were opened 
in ImageQuest™ software (Thermo Fisher Scientific, 
San José, CA) and the precursor mass of tamoxifen (m/z 
372.233) was extracted showing its localization within 
the tissue sections. Screen shots were taken of the dis-
tribution of tamoxifen precursor ion normalized on total 
ion count (TIC). For determination of signal response, 
the precursor ion intensities of tamoxifen were normal-
ized to the CHCA signal (m/z 372.092 of [2  M +  H]+) 
and plotted against the calculated concentrations (0.001–
10 µg/mL), see Additional file 1: Figure S1.
After removal of the matrix, the slides were stained 
with Mayer’s hematoxylin-eosin (HE). Cover slipped 
H and E-stained slides were loaded into the slide scan-
ner (Mirax Midi Slide Scanner, Zeiss, Germany) to take 
detailed images for selection of regions of interest at 
high resolution [26]. The raw image files were opened 
in Aperio ImageScope Viewer v12.1 (Leica Biosystems 
Imaging Inc., Vista, CA), where a photo of the detailed 
HE scan could be taken and saved as a .tiff image file. The 
same HE images were annotated by a pathologist high-
lighting tumor cell dense regions using the Path XL web-
based software tool. These annotations were transferred 
and overlaid on to extracted ion maps of tamoxifen for 
comparison of tumor areas with stroma within each sec-
tion using the open source image processing software Fiji 
(ImageJ v2.0.0; http://imagej.net). Outlines of the areas 
representing the malignant tissue were directly derived 
from the highlights made by the pathologist. Outlines of 
the areas representing unaffected stroma were obtained 
from the images of HE stained tissue, in which the ROIs 
representing the tumor areas were filled with background 
color. The images were then converted to binary repre-
sentation, and “Create Selection” function was applied 
to outline the tissue sections and create regions of inter-
est which excluded tumor areas and spaces not occupied 
by cells. The mean intensity values were determined and 
used for statistical evaluation calculating the p value in 
two-tailed paired t test.
Results
Characterization of tamoxifen by MALDI‑MS
Tamoxifen was obtained in the form of a commercial 
medicine (Zitazonium™) formulated as tablets with 
10  mg active compound. Following initial dissolving of 
a pill, the entire content was used for determining the 
ionization properties of tamoxifen on a MALDI LTQ 
Orbitrap XL mass spectrometer. A singly, positively 
charged precursor ion of tamoxifen (m/z 372.233) was 
readily observed in full mass spectra as shown in Fig. 1a. 
Following mass isolation of this peak, the CID fragmen-
tation in the linear ion trap, applying 35  % normalized 
collision energy, has produced a complex tandem spec-
trum indicating multiple fragment ions of tamoxifen (see 
Fig. 1b).
The same precursor ion of tamoxifen (m/z 372.233) was 
observed in tissue sections when a solution of the drug 
was deposited manually and matrix was sprayed on the 
surface, as shown in Additional file 2: Figure S2. However, 
the typical peaks of CHCA were also clearly detectable 
in these spectra, which was due to the high concentra-
tion of matrix required for sufficient ionization on tissue 
surface. Under such conditions, the well-known ion sup-
pression effect may contribute to the generally lower sig-
nal intensities of drug analytes detected in MALDI-MSI 
experiments. Utilizing the superior mass resolution and 
accuracy of the Orbitrap mass analyzer, full scan mode 
was chosen for data acquisition in imaging mode rather 
than tandem mass spectra.
The signal intensities of tamoxifen precursor ion were 
measured on a stainless steel MALDI target plate in the 
concentration range between 0.001–10  µg/mL. It was 
found that 10  µg/mL tamoxifen could overfill up the 
Orbitrap (asking for 106 target ions) but good linear-
ity was obtained between 100–104 ng/mL concentration 
(see Additional file  1: Figure S1). Accordingly, the LOD 
of tamoxifen was estimated to be less than 1  ng/mL 
(2.7 nM) on target plate. Due to the different ionization 
properties of tamoxifen on a tissue surface, this reference 
correlation was not used to estimate the actual amount 
of drug in tissue sections. Instead, the selected regions 
of interests (ROIs) of tumor cell dense and stroma areas 
were compared based on careful annotations of these 
regions by a trained pathologist (see “Localization of 
tamoxifen in human breast tumor sections” section).
Localization of tamoxifen in human breast tumor sections
A visual comparison of tumors suggested that ER-neg-
ative tissues had a tendency of larger continuous areas 
covered by cancer cells in contrast to the ER-positive 
tumor sections that typically displayed discontinuous, 
scattered cancer cell patterns (Fig.  2a). Dried breast 
tumor sections on glass slides were treated with a tamox-
ifen solution (2  µg/mL) according to the experimental 
model introduced previously [25, 26]. The general con-
cept of this model is based on manual deposition of a 
drug on tissue surface and incubation at room tempera-
ture before matrix application. Following the sample 
preparation steps, MALDI-MSI analysis revealed the 
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Fig. 1 Ionization characteristics of tamoxifen (0.1 mg/mL in water) as measured with 3.5 mg/mL CHCA on a stainless steel MALDI target plate. a A 
full mass spectrum of tamoxifen obtained at 60,000 resolution using the Orbitrap mass analyzer and b a tandem mass spectrum of tamoxifen isolat‑
ing the m/z 372.23 and CID fragmented in the linear ion trap mass analyzer
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localization of tamoxifen within tumor sections, show-
ing heterogeneous distributions of its precursor ion that 
followed histological structures, as typical examples 
shown in Fig. 2b. Additionally, Additional file 3: Figure S3 
presents all breast tumor sections analyzed by MALDI-
MSI using identical experimental parameters. In order 
to compensate for the ion suppression usually associ-
ated with MALDI-MS analysis, the precursor ion (m/z 
372.233) intensities were always normalized on TIC.
In accordance with previous observations [25, 27], in 
several instances, lower signal intensities of tamoxifen 
were observed in tumor cell dense regions as annotated 
in yellow lines by a trained pathologist (see Fig. 2a). How-
ever, the complex patterns of tumor cells, especially in 
the ER-positive tissue sections, limited the visual com-
parison of drug signal distributions. We have utilized the 
thorough pathological annotations and created masks 
in an imaging software, dividing the area of each tis-
sue section to tumor and stroma cell covered regions. 
These histology derived ROIs were then transferred onto 
extracted ion maps of tamoxifen (normalized on TIC) 
in monochromic MS images. The mean signal intensi-
ties in tumor and stromal regions were determined in 
each tissue section and presented in Table  1. The ratios 
of the mean signal intensities in these regions were evalu-
ated for differentiating ER-negatives and ER-positives, 
as data indicated higher signal intensities in tumor cells 
in three out of four ER-positive samples. The statistical 
analysis, applying paired t test, indicated a significant dif-
ference between the ER groups in the investigated sam-
ples (p = 0.01). Although, the distributions of tamoxifen 
signal intensities displayed different profiles, they were 
always similar in tumor cells and stroma ROIs of the 
same tissue (see histograms in Additional file  4 Figure 
S4).
Discussion
We have analyzed ten human breast tumors stratified for 
ER status, following interaction with a manually depos-
ited tamoxifen solution, as described previously [25, 26]. 
The application of a homogeneous solution on the tissue 
surface permitted a free movement of drug molecules, 
driven by physical transport (diffusion), and allowed for 
various molecular interactions. Although, the cells in 
the tissue sections were dead but most of them were cut 
open by sectioning and became rehydrated during sam-
ple preparation, rendering a suitable environment for 
interactions between drug and protein molecules. We 
can speculate that proteins with preserved conformation 
might even display weak biological activity facilitating 
specific interactions with ligands.
Following incubation in a humidity chamber with 
controlled conditions to treat all sections identically, 
including the removal of drug solution and rinsing, the 
samples were dried in air at room temperature. Similar 
control was pertained during matrix application, produc-
ing homogeneous crystallization with even thickness that 
was achieved by deposition of the same amount of CHCA 
over an area in each section. Visual investigation of the 
matrix layers using a stereo microscope at 5× magnifica-
tion, could not reveal any profound differences in crystal 
size or coverage. We have perfected airbrush deposition 
and achieved good reproducibility in several studies pre-
viously and could occasionally recognize tissue structure 
under the matrix layer in large sections with greater his-
tological heterogeneity only. Ionization efficiency there-
fore assumed to be similar throughout the experiments, 
which was seen in TIC images. Furthermore, the tissue 
sections were fixated to the glass surface using MeOH 
wash that could effectively remove abundant lipids, nor-
malizing their levels between stroma and cancer cells. 
Consequently, apparent variations in signals of tamox-
ifen observed in tumor and stromal cells assumed to be 
accounted for differential interactions with the ligands, 
resulting in their accumulation in spaces with higher 
density of target molecules, such as ER.
In general, it is not known that ER-negative tumors 
have a more solid way of growing. Although ER-negative 
tumors are more frequently low differentiated tumors 
and histological grade 3 indicating a worse prognosis. 
ER-negative tumors are more frequently proliferating, 
with a higher Ki67 [18]. Hence, tumors with low differ-
entiation, high histological grade and high proliferations 
markers may have a tendency of growing more solidly. 
This is in line with our findings with a tendency of larger 
cancer cell fields as the pattern of growing in the ER-neg-
ative tumors.
The identified precursor mass of tamoxifen (m/z 
372.233) was extracted and mapped over the tissue sec-
tions after MALDI-MSI data acquisition. It was found 
that the drug signal distributed heterogeneously over 
the tissue sections showing characteristically higher 
intensities from stroma compared to tumor cell dense 
areas typically in ER-negative sections, whereas ER-pos-
itive tissue sections displayed an opposite distribution of 
tamoxifen signals (Table  1). The results of ER-negative 
tissues agreed well with previous findings when a drug 
solution was spotted on heterogeneous tumor surface 
un equal amount at each position [27]. It was hypothe-
sized that tumor cells might had different surface prop-
erties regulated by their altered molecular composition 
as compared with normal (stromal) cells. Additionally, 
this observation is in agreement with MALDI-MSI data 
from in  vivo animal models displaying drug signals sig-
nificantly lower in cancer cells [22]. Furthermore, it has 
been previously shown that the protein expression of 
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Fig. 2 Examples of tamoxifen localization in experimental model analysis showing the precursor ion (m/z 372.233) distribution in an ER‑negative 
(left panels) and an ER‑positive (right panels) phenotype tissue section. The dotted lines define the areas covered by tumor cells as determined by a 
pathologist in H and E images (a). The extracted ion maps of the tamoxifen precursor ion were normalized on TIC and the same intensity scale was 
used to compare tumor sections. The tumor and stroma ROIs, that were used for quantitative comparison, were highlighted in yellow (b) and red (c), 
respectively
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ER-positive and ER-negative tumors differed significantly 
[28]. However, the direct comparison of ER stratified tis-
sues likely reflects the differences in levels of ER expres-
sion in tumor cells.
MSI provides a more universal approach to study drug 
binding to characterize receptor distribution in tissue 
sections than the radio-ligand method [3], without a need 
to use radioactive compounds. In case the target receptor 
is expressed but its function is altered due to mutations 
[29], the drug binding/retention capacity may be com-
pared for tumor and stroma cells in ER-negative and ER-
positive cancer. In this way, the MSI based methodology 
may serve as a predictor for therapy response revealing 
with physiological drug distribution that can be studied 
in patient biopsies following administration. This finding 
has to be further investigated and verified in future stud-
ies with breast cancer samples.
Conclusions
This proof-of-principle study using sections of stratified 
breast cancer tumors with manually overlaid tamoxifen 
has revealed histology dictated spatial localizations of 
the drug molecules as detected by MALDI-MSI. We have 
shown distributions of tamoxifen in both ER-positive and 
ER-negative tumors, detecting the drug at significantly 
lower intensities in tumor cells compared with stroma 
in ER-negative samples. However, ER-negative tissue 
sections displayed larger continuous areas covered with 
tumor cells than that of ER-positive sections, these later 
ones displayed accumulated tamoxifen in tumor cells. 
Based on our findings, this experimental model can be 
useful in characterizing drugs in tumors and applied to 
further investigate molecular mechanisms of drug uptake 
and distribution.
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Additional file 1: Figure S1. Quantification of tamoxifen on MALDI tar‑
get plate using normalization of signal intensity on the [2 M + H]+ matrix 
peak (m/z 379.092). A dilution series of tamoxifen solutions was deposited 
and mixed with the matrix solution to obtain homogenous crystallization 
before MALDI‑MS analysis.
Additional file 2: Figure S2. Ionization characteristics of tamoxifen 
(0.1 mg/mL in water) as measured with 7.5 mg/mL CHCA directly on 
a section of human breast tumor. MALDI‑MS analysis conditions were 
identical with those used for MALDI‑MSI.
Additional file 3: Figure S3. Localization of tamoxifen in ER‑negative 
(n = 4) and ER‑positive (n = 4) breast tumor sections by MALDI‑MSI 
analysis highlighting areas with high cancer cell densities as determined 
and shown in H and E stained sections. MALDI‑MSI data acquisition 
parameters were identical with those results presented in Fig. 2.
Additional file 4: Figure S4. Distribution of signal intensities of tamox‑
ifen in tumor and stroma ROIs. The mean intensities, as determined by 
image analysis, are presented in Table 1.
Table 1 Summary of image analysis
The mean signal intensity of the tamoxifen precursor ion (m/z 372.233) was 
determined in annotated tumor and stroma regions within each tissue section 
using the normalized MS images. The ratios of mean intensities (tumor/stroma) 
were calculated for statistical t test that showed significant differences between 
the ER groups (p = 0.01)





 Tumor 20,633 141.956 0.961
 Stroma 51,585 147.683
21498/ER−
 Tumor 46,556 14.861 0.555
 Stroma 174,838 26.79
21505/ER−
 Tumor 57,135 35.279 1.082
 Stroma 121,614 32.601
21524/ER−
 Tumor 41,870 71.572 0.779
 Stroma 99,257 91.917
21506/ER+
 Tumor 4198 60.243 1.138
 Stroma 176,973 52.923
21508/ER+
 Tumor 29,101 62.652 0.849
 Stroma 87,341 73.769
21509/ER+
 Tumor 45,132 14.877 1.278
 Stroma 120,119 11.637
21557/ER+
 Tumor 28,673 28.369 1.151
 Stroma 62,461 24.643
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